These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35138549)

  • 21. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
    Carney BL; Hadland SE; Bagley SM
    Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 27. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
    Wood CA; Duello A; Miles J; Lohmann B; Gochez-Kerr T; Richardson K; Anderson-Harper R; Winograd RP
    J Subst Abuse Treat; 2022 Jul; 138():108747. PubMed ID: 35248406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
    Benville JR; Compton P; Giordano NA; Cheatle MD
    Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
    Chalhoub RM; Kalivas PW
    Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of Drugs Used to Treat Opioid Use Disorder.
    Aschenbrenner DS
    Am J Nurs; 2018 Aug; 118(8):25. PubMed ID: 30048283
    [No Abstract]   [Full Text] [Related]  

  • 32. Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review.
    Veazie S; Mackey K; Peterson K; Bourne D
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):945-953. PubMed ID: 33145688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing emergency department patients with opioid use disorder.
    Hazekamp CS; Sacco D
    Emerg Med Pract; 2024 Jun; 26(6):1-24. PubMed ID: 38768011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
    Chang DC; Klimas J; Wood E; Fairbairn N
    Am J Drug Alcohol Abuse; 2018; 44(2):143-146. PubMed ID: 29190156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
    Fanucchi L; Springer SA; Korthuis PT
    Curr HIV/AIDS Rep; 2019 Feb; 16(1):1-6. PubMed ID: 30684117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
    Gainer DM; Crawford TN; Fischer KB; Wright MD
    J Subst Abuse Treat; 2021 Feb; 121():108195. PubMed ID: 33357605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.